Biotherapeutics Cell Line Development Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global biotherapeutics cell line development market looks promising with opportunities in bioproduction, tissue engineering & regenerative medicine, toxicity testing, research, and drug discovery applications. The global biotherapeutics cell line development market is expected to grow with a CAGR of 6%-8% from 2020 to 2025. The major drivers for this market are increase in geriatric population and prevalence of diseases, government initiatives to boost biotechnology & pharmaceutical sectors, and development of advanced technologies to cater to the rising demand for monoclonal antibodies.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biotherapeutics cell line development market report, please download the report brochure.
In this market, single cell cloning is the fastest growing process of biotherapeutics cell line development, whereas outsourced is the fastest growing CLD option. Growth in various segments of the biotherapeutics cell line development market are given below:
The study includes trends and forecast for the global biotherapeutics cell line development market by process, CLD option, and region as follows:
By Process [Value ($ Million) shipment analysis for 2014 – 2025]:
Transfection & Selection and Single Cell Cloning
Consumable
By CLD Option [Value ($ Million) shipment analysis for 2014 – 2025]:
In-House
Outsourced
Do-It-Yourself
Hybrid
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
Spain
Italy
France
Asia Pacific
China
Japan
India
The Rest of the World
Brazil
Some of the biotherapeutics cell line development companies profiled in this report include Merck KGaA, Becton, Dickinson and Company (BD), Danaher, Boehringer Ingelheim Group, Thermo Fisher Scientific, Lonza Group, Probiogen, Solentim, Selexis, and Sysmex.
Lucintel forecasts that single cell cloning will remain the largest process segment over the forecast period due to rise in demand for biotherapeutics, increase in adoption of instruments, such as FACS (Fluorescence-Activated Cell Sorting) & ClonePix, and higher throughput nature of this method.
Within this market, outsource will remain the largest CLD option segment over the forecast period. The increase in demand for outsourced products, cost saving, and rapid delivery of products are some of the major factors that drive the outsource segment.
North America will remain the largest region over the forecast period due to high funding in new biological drugs, rise in geriatric population, increase in prevalence of various diseases in the developed countries of the region, and growth in government funding for research and development activities.
Features of the Global Biotherapeutics Cell Line Development Market
Market Size Estimates: Global biotherapeutics cell line development market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global biotherapeutics cell line development market size by various segments, such as process and CLD option in terms of value.Regional Analysis: Global biotherapeutics cell line development market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different process, CLD option, and region for the global biotherapeutics cell line development market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biotherapeutics cell line development market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global biotherapeutics cell line development market by process (transfection & selection and single cell cloning and consumable), CLD option (in-house, outsourced, do-it-yourself, and hybrid), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biotherapeutics cell line development market?
Q.5 What are the business risks and threats to the global biotherapeutics cell line development market?
Q.6 What are the emerging trends in this biotherapeutics cell line development market and the reasons behind them?
Q.7 What are some changing demands of customers in this biotherapeutics cell line development market?
Q.8 What are the new developments in this biotherapeutics cell line development market? Which companies are leading these developments?
Q.9 Who are the major players in this biotherapeutics cell line development market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biotherapeutics cell line development market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biotherapeutics cell line development market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Process (Transfection & Selection and Single Cell Cloning and Consumable) and CLD Option (In-House, Outsourced, Do-It-Yourself, and Hybrid)
Regional Scope North America (USA, Mexico, and Canada), Europe (Germany, United Kingdom, Spain, Italy, and France), Asia (China, Japan, and India), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global biotherapeutics cell line development market looks promising with opportunities in bioproduction, tissue engineering & regenerative medicine, toxicity testing, research, and drug discovery applications. The global biotherapeutics cell line development market is expected to grow with a CAGR of 6%-8% from 2020 to 2025. The major drivers for this market are increase in geriatric population and prevalence of diseases, government initiatives to boost biotechnology & pharmaceutical sectors, and development of advanced technologies to cater to the rising demand for monoclonal antibodies.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biotherapeutics cell line development market report, please download the report brochure.
In this market, single cell cloning is the fastest growing process of biotherapeutics cell line development, whereas outsourced is the fastest growing CLD option. Growth in various segments of the biotherapeutics cell line development market are given below:
The study includes trends and forecast for the global biotherapeutics cell line development market by process, CLD option, and region as follows:
By Process [Value ($ Million) shipment analysis for 2014 – 2025]:
Transfection & Selection and Single Cell Cloning
Consumable
By CLD Option [Value ($ Million) shipment analysis for 2014 – 2025]:
In-House
Outsourced
Do-It-Yourself
Hybrid
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
Spain
Italy
France
Asia Pacific
China
Japan
India
The Rest of the World
Brazil
Some of the biotherapeutics cell line development companies profiled in this report include Merck KGaA, Becton, Dickinson and Company (BD), Danaher, Boehringer Ingelheim Group, Thermo Fisher Scientific, Lonza Group, Probiogen, Solentim, Selexis, and Sysmex.
Lucintel forecasts that single cell cloning will remain the largest process segment over the forecast period due to rise in demand for biotherapeutics, increase in adoption of instruments, such as FACS (Fluorescence-Activated Cell Sorting) & ClonePix, and higher throughput nature of this method.
Within this market, outsource will remain the largest CLD option segment over the forecast period. The increase in demand for outsourced products, cost saving, and rapid delivery of products are some of the major factors that drive the outsource segment.
North America will remain the largest region over the forecast period due to high funding in new biological drugs, rise in geriatric population, increase in prevalence of various diseases in the developed countries of the region, and growth in government funding for research and development activities.
Features of the Global Biotherapeutics Cell Line Development Market
Market Size Estimates: Global biotherapeutics cell line development market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global biotherapeutics cell line development market size by various segments, such as process and CLD option in terms of value.Regional Analysis: Global biotherapeutics cell line development market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different process, CLD option, and region for the global biotherapeutics cell line development market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biotherapeutics cell line development market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global biotherapeutics cell line development market by process (transfection & selection and single cell cloning and consumable), CLD option (in-house, outsourced, do-it-yourself, and hybrid), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biotherapeutics cell line development market?
Q.5 What are the business risks and threats to the global biotherapeutics cell line development market?
Q.6 What are the emerging trends in this biotherapeutics cell line development market and the reasons behind them?
Q.7 What are some changing demands of customers in this biotherapeutics cell line development market?
Q.8 What are the new developments in this biotherapeutics cell line development market? Which companies are leading these developments?
Q.9 Who are the major players in this biotherapeutics cell line development market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biotherapeutics cell line development market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biotherapeutics cell line development market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Process (Transfection & Selection and Single Cell Cloning and Consumable) and CLD Option (In-House, Outsourced, Do-It-Yourself, and Hybrid)
Regional Scope North America (USA, Mexico, and Canada), Europe (Germany, United Kingdom, Spain, Italy, and France), Asia (China, Japan, and India), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biotherapeutics Cell Line Development Market Trends and Forecast
3.3: Global Biotherapeutics Cell Line Development Market by Process
3.3.1: Transfection & Selection
3.3.2: Single Cell Cloning
3.4: Global Biotherapeutics Cell Line Development Market by CLD Option
3.4.1: In-House
3.4.2: Outsourced
3.4.3: Do-It-Yourself
3.4.4: Hybrid
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biotherapeutics Cell Line Development Market by Region
4.2: North American Biotherapeutics Cell Line Development Market
4.2.1: Market by Process: Transfection & Selection and Single Cell Cloning
4.2.2: Market by CLD Option: In-House, Outsourced, Do-It-Yourself, and Hybrid
4.2.4: The United States Biotherapeutics Cell Line Development Market
4.2.5: The Canadian Biotherapeutics Cell Line Development Market
4.2.6: The Mexican Biotherapeutics Cell Line Development Market
4.3: European Biotherapeutics Cell Line Development Market
4.3.1: Market by Process: Transfection & Selection and Single Cell Cloning
4.3.2: Market by CLD Option: In-House, Outsourced, Do-It-Yourself, and Hybrid
4.3.3: The German Biotherapeutics Cell Line Development Market
4.3.4: The United Kingdom Biotherapeutics Cell Line Development Market
4.3.5: The Spain Biotherapeutics Cell Line Development Market
4.3.6: The Italy Biotherapeutics Cell Line Development Market
4.3.7: The French Biotherapeutics Cell Line Development Market
4.4: APAC Biotherapeutics Cell Line Development Market
4.4.1: Market by Process: Transfection & Selection and Single Cell Cloning
4.4.2: Market by CLD Option: In-House, Outsourced, Do-It-Yourself, and Hybrid
4.4.3: The Chinese Biotherapeutics Cell Line Development Market
4.4.4: The Indian Biotherapeutics Cell Line Development Market
4.4.5: The Japanese Biotherapeutics Cell Line Development Market
4.5: ROW Biotherapeutics Cell Line Development Market
4.5.1: Market by Process: Transfection & Selection and Single Cell Cloning
4.5.2: Market by CLD Option: In-House, Outsourced, Do-It-Yourself, and Hybrid
4.5.3: Brazilian Biotherapeutics Cell Line Development Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biotherapeutics Cell Line Development Market by Process
7.1.2: Growth Opportunities for the Global Biotherapeutics Cell Line Development Market by CLD Option
7.1.3: Growth Opportunities for the Global Biotherapeutics Cell Line Development Market by Region
7.2: Emerging Trends in the Global Biotherapeutics Cell Line Development Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biotherapeutics Cell Line Development Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biotherapeutics Cell Line Development Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Merck KGaA
8.2: Becton, Dickinson and Company (BD)
8.3: Danaher Corporation
8.4: Boehringer Ingelheim Group
8.5: Therm Fisher Scientific, Inc.
8.6: Company
8.7: Company
8.8: Company
8.9: Company
8.10: Company
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biotherapeutics Cell Line Development Market Trends and Forecast
3.3: Global Biotherapeutics Cell Line Development Market by Process
3.3.1: Transfection & Selection
3.3.2: Single Cell Cloning
3.4: Global Biotherapeutics Cell Line Development Market by CLD Option
3.4.1: In-House
3.4.2: Outsourced
3.4.3: Do-It-Yourself
3.4.4: Hybrid
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biotherapeutics Cell Line Development Market by Region
4.2: North American Biotherapeutics Cell Line Development Market
4.2.1: Market by Process: Transfection & Selection and Single Cell Cloning
4.2.2: Market by CLD Option: In-House, Outsourced, Do-It-Yourself, and Hybrid
4.2.4: The United States Biotherapeutics Cell Line Development Market
4.2.5: The Canadian Biotherapeutics Cell Line Development Market
4.2.6: The Mexican Biotherapeutics Cell Line Development Market
4.3: European Biotherapeutics Cell Line Development Market
4.3.1: Market by Process: Transfection & Selection and Single Cell Cloning
4.3.2: Market by CLD Option: In-House, Outsourced, Do-It-Yourself, and Hybrid
4.3.3: The German Biotherapeutics Cell Line Development Market
4.3.4: The United Kingdom Biotherapeutics Cell Line Development Market
4.3.5: The Spain Biotherapeutics Cell Line Development Market
4.3.6: The Italy Biotherapeutics Cell Line Development Market
4.3.7: The French Biotherapeutics Cell Line Development Market
4.4: APAC Biotherapeutics Cell Line Development Market
4.4.1: Market by Process: Transfection & Selection and Single Cell Cloning
4.4.2: Market by CLD Option: In-House, Outsourced, Do-It-Yourself, and Hybrid
4.4.3: The Chinese Biotherapeutics Cell Line Development Market
4.4.4: The Indian Biotherapeutics Cell Line Development Market
4.4.5: The Japanese Biotherapeutics Cell Line Development Market
4.5: ROW Biotherapeutics Cell Line Development Market
4.5.1: Market by Process: Transfection & Selection and Single Cell Cloning
4.5.2: Market by CLD Option: In-House, Outsourced, Do-It-Yourself, and Hybrid
4.5.3: Brazilian Biotherapeutics Cell Line Development Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biotherapeutics Cell Line Development Market by Process
7.1.2: Growth Opportunities for the Global Biotherapeutics Cell Line Development Market by CLD Option
7.1.3: Growth Opportunities for the Global Biotherapeutics Cell Line Development Market by Region
7.2: Emerging Trends in the Global Biotherapeutics Cell Line Development Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biotherapeutics Cell Line Development Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biotherapeutics Cell Line Development Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Merck KGaA
8.2: Becton, Dickinson and Company (BD)
8.3: Danaher Corporation
8.4: Boehringer Ingelheim Group
8.5: Therm Fisher Scientific, Inc.
8.6: Company
8.7: Company
8.8: Company
8.9: Company
8.10: Company
